^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastroesophageal Cancer

    Related cancers:
    Apply
    A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer (NCT06038578)
    Phase 2
    Toray Industries, Inc
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    10/04/2023
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    CAPRIN1
    |
    paclitaxel • Cyramza (ramucirumab) • TRK-950
    A Study of SGN-B6A in Advanced Solid Tumors (SGNB6A-001) (NCT04389632)
    Phase 1
    Seagen Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    06/08/2020
    Primary completion :
    11/30/2026
    Completion :
    02/28/2028
    HER-2
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)
    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    08/09/2021
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    HER-2 • TP53 • ATM • RAS • CD4
    |
    HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)
    Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors (D9750C00001) (NCT06005493)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    07/11/2023
    Primary completion :
    12/16/2026
    Completion :
    12/16/2026
    CLDN18
    |
    CLDN18.2 positive • CLDN1 positive
    |
    AZD5863
    A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors (BG-68501-101) (NCT06257264)
    Phase 1
    BeiGene
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    03/11/2024
    Primary completion :
    02/28/2028
    Completion :
    02/28/2028
    HER-2
    |
    HER-2 negative
    |
    fulvestrant
    A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer (NCT06123338)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    02/01/2024
    Primary completion :
    11/30/2027
    Completion :
    11/30/2027
    HER-2
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • capecitabine • oxaliplatin
    Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (NCT05836584)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    12/06/2023
    Primary completion :
    10/31/2027
    Completion :
    10/31/2027
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101) (NCT05052801)
    Phase 3
    Amgen
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    03/07/2022
    Primary completion :
    08/18/2025
    Completion :
    08/18/2025
    FGFR2
    |
    FGFR2 overexpression • FGFR2b overexpression
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
    A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (NCT05544929)
    Phase 1
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/26/2022
    Primary completion :
    02/20/2026
    Completion :
    02/20/2026
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115
    A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction (NCT04661150)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    03/12/2021
    Primary completion :
    05/08/2023
    Completion :
    06/30/2026
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • capecitabine • oxaliplatin
    Futibatinib in Patients With Specific FGFR Aberrations (TAS-120-202) (NCT04189445)
    Phase 2
    Taiho Oncology, Inc.
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    08/24/2020
    Primary completion :
    11/11/2024
    Completion :
    03/31/2025
    FGFR2
    |
    FGFR2 amplification • FGFR1 rearrangement
    |
    Lytgobi (futibatinib)
    A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors (MCLA-158-CL01) (NCT03526835)
    Phase 1/2
    Merus N.V.
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    05/02/2018
    Primary completion :
    11/01/2025
    Completion :
    11/01/2027
    EGFR
    |
    EGFR amplification
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • petosemtamab (MCLA-158)
    Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) (NCT03539822)
    Phase 1/2
    Anwaar Saeed
    Recruiting
    Last update posted :
    01/14/2025
    Initiation :
    10/22/2018
    Primary completion :
    01/31/2027
    Completion :
    01/31/2028
    MSI
    |
    RAS wild-type
    |
    Imfinzi (durvalumab) • Cabometyx (cabozantinib tablet) • Imjudo (tremelimumab-actl)
    A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) (NCT06764875)
    Phase 3
    AstraZeneca
    Not yet recruiting
    Last update posted :
    01/09/2025
    Initiation :
    03/28/2025
    Primary completion :
    04/27/2029
    Completion :
    12/09/2030
    PD-L1
    |
    Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936)
    Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors (NCT04900818)
    Phase 1
    I-Mab Biopharma US Limited
    Recruiting
    Last update posted :
    01/03/2025
    Initiation :
    06/29/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    PD-L1 • CLDN18
    |
    CLDN18.2 positive
    |
    Opdivo (nivolumab) • givastomig (TJ-CD4B)
    Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma (TORCH-G) (NCT06728657)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    12/11/2024
    Initiation :
    07/01/2024
    Primary completion :
    12/31/2025
    Completion :
    12/31/2028
    PD-L1
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tyvyt (sintilimab) • capecitabine • oxaliplatin
    Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer (NCT06713993)
    Phase N/A
    Semmelweis University
    Recruiting
    Last update posted :
    12/03/2024
    Initiation :
    09/10/2024
    Primary completion :
    09/30/2029
    Completion :
    09/10/2034
    IL6 • GDF15 • IGF1
    Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers (MK3475-A53) (NCT05379972)
    Phase 2
    University of Colorado, Denver
    Recruiting
    Last update posted :
    11/26/2024
    Initiation :
    01/12/2023
    Primary completion :
    12/01/2025
    Completion :
    12/01/2028
    HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4
    |
    HRD
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer (DECIPHER) (NCT05965479)
    Phase 2
    University of Southampton
    Recruiting
    Last update posted :
    11/11/2024
    Initiation :
    04/10/2024
    Primary completion :
    03/31/2026
    Completion :
    04/30/2028
    HER-2
    |
    HER-2 overexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer (NCT05650827)
    Phase N/A
    Rigshospitalet, Denmark
    Recruiting
    Last update posted :
    11/05/2024
    Initiation :
    02/24/2023
    Primary completion :
    12/01/2025
    Completion :
    12/01/2027
    IFNG • IL6 • TNFA • IL10 • CRP
    Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) (NCT04704934)
    Phase 3
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    10/24/2024
    Initiation :
    05/21/2021
    Primary completion :
    10/01/2025
    Completion :
    02/01/2026
    HER-2
    |
    HER-2 positive • HER-2 amplification
    |
    paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Cyramza (ramucirumab)
    Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1 (HEPATOXALI) (NCT06649474)
    Phase N/A
    University Hospital, Clermont-Ferrand
    Recruiting
    Last update posted :
    10/18/2024
    Initiation :
    09/06/2024
    Primary completion :
    06/30/2028
    Completion :
    06/30/2028
    HMGB1
    |
    oxaliplatin
    Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer (NCT02962063)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    10/16/2024
    Initiation :
    11/01/2016
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    HER-2
    |
    HER-2 positive
    |
    carboplatin • Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)
    Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (SEQUEL) (NCT04069273)
    Phase 2
    Harry H Yoon
    Recruiting
    Last update posted :
    07/02/2024
    Initiation :
    12/01/2020
    Primary completion :
    06/11/2025
    Completion :
    12/10/2025
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • paclitaxel • Cyramza (ramucirumab)
    Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (NCT04152499)
    Phase 1/2
    Klus Pharma Inc.
    Recruiting
    Last update posted :
    06/24/2024
    Initiation :
    02/28/2020
    Primary completion :
    08/01/2025
    Completion :
    07/16/2026
    EGFR • HER-2 • MSI • BRCA • TACSTD2
    |
    MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation
    |
    Jiataile (sacituzumab tirumotecan)
    RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) (NCT04879368)
    Phase 3
    Australasian Gastro-Intestinal Trials Group
    Active, not recruiting
    Last update posted :
    05/15/2024
    Initiation :
    06/01/2021
    Primary completion :
    06/01/2025
    Completion :
    06/01/2026
    HER-2
    |
    HER-2 positive
    |
    Opdivo (nivolumab) • docetaxel • albumin-bound paclitaxel • Stivarga (regorafenib) • irinotecan • Lonsurf (trifluridine/tipiracil)
    Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (NCT03798626)
    Phase 1
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/14/2024
    Initiation :
    05/22/2019
    Primary completion :
    03/01/2023
    Completion :
    12/30/2024
    CRP
    |
    Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)
    Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer (NCT06109467)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    01/12/2024
    Primary completion :
    04/01/2028
    Completion :
    04/01/2028
    HER-2
    |
    HER-2 overexpression • HER-2 amplification
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • Nerlynx (neratinib) • oxaliplatin • leucovorin calcium
    KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer (NCT03342937)
    Phase 2
    Duke University
    Completed
    Last update posted :
    03/13/2024
    Initiation :
    01/11/2018
    Primary completion :
    02/06/2023
    Completion :
    02/06/2023
    HER-2
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • capecitabine • oxaliplatin
    A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer (NCT04161781)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    03/08/2024
    Initiation :
    11/12/2019
    Primary completion :
    03/06/2024
    Completion :
    03/06/2024
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab)
    A Study of Amivantamab in People With Esophagogastric Cancer (NCT05117931)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    12/02/2021
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    HER-2
    |
    MET amplification • EGFR amplification
    |
    Rybrevant (amivantamab-vmjw)
    A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies (NCT03321630)
    Phase 2
    NYU Langone Health
    Completed
    Last update posted :
    02/29/2024
    Initiation :
    10/24/2017
    Primary completion :
    03/10/2023
    Completion :
    01/16/2024
    HER-2
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma (NCT03950271)
    Phase 2
    Henan Cancer Hospital
    Active, not recruiting
    Last update posted :
    02/28/2024
    Initiation :
    01/20/2020
    Primary completion :
    01/31/2024
    Completion :
    12/31/2026
    HER-2 • PD-L1 • MSI
    |
    Herceptin (trastuzumab) • AiRuiKa (camrelizumab) • capecitabine • oxaliplatin
    Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors (NCT03983954)
    Phase 1
    NeoTX Therapeutics Ltd.
    Active, not recruiting
    Last update posted :
    02/22/2024
    Initiation :
    10/10/2019
    Primary completion :
    10/01/2026
    Completion :
    10/01/2026
    HER-2 • ER • TPBG
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer (NCT02830594)
    Phase 2
    City of Hope Medical Center
    Completed
    Last update posted :
    02/19/2024
    Initiation :
    10/05/2016
    Primary completion :
    01/20/2022
    Completion :
    01/16/2024
    HER-2 • PD-L2
    |
    HER-2 overexpression
    |
    Keytruda (pembrolizumab)
    AB122 Platform Study (NCT04999761)
    Phase 1
    Taiho Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    02/16/2024
    Initiation :
    06/01/2021
    Primary completion :
    05/01/2026
    Completion :
    05/01/2026
    KRAS • NRAS
    |
    KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation
    |
    Avastin (bevacizumab) • Cyramza (ramucirumab) • Lytgobi (futibatinib) • Yutuo (zimberelimab) • Lonsurf (trifluridine/tipiracil) • Jeselhy (pimitespib) • pamufetinib (TAS-115)
    Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer (NCT04522336)
    Phase 1
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/16/2024
    Initiation :
    09/16/2020
    Primary completion :
    07/18/2024
    Completion :
    07/18/2024
    PD-L1
    |
    Keytruda (pembrolizumab) • docetaxel • 5-fluorouracil • oxaliplatin • fluorouracil topical
    A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (NCT04950322)
    Phase 3
    Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    Active, not recruiting
    Last update posted :
    02/07/2024
    Initiation :
    12/06/2021
    Primary completion :
    03/15/2025
    Completion :
    06/30/2025
    HER-2
    |
    HER-2 overexpression • HER-2 amplification
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • retlirafusp alfa (SHR-1701)
    Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer (NCT03196232)
    Phase 2
    George Albert Fisher
    Completed
    Last update posted :
    01/23/2024
    Initiation :
    09/13/2017
    Primary completion :
    05/29/2018
    Completion :
    05/29/2018
    HER-2
    |
    Keytruda (pembrolizumab) • epacadostat (INCB024360)